Fabrication of a carboxylesterases-activated near-infrared fluorescence probe for assisting hepatocellular carcinoma surgery in mice and clinical blood serum testing

被引:0
作者
Li, Zhen [1 ]
Hong, Can [2 ]
Zhang, Wanting [2 ]
Guo, Limin [3 ]
Cao, Junrong [4 ]
He, Longwei [2 ,5 ]
Zhou, Jia [2 ]
He, Xiubao [1 ]
机构
[1] First Peoples Hosp Chenzhou, Dept Ultrason, Med Ctr, Chenzhou 423000, Hunan, Peoples R China
[2] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Ultrasound Med, Hengyang 421001, Hunan, Peoples R China
[3] First Peoples Hosp Chenzhou, Dept Pediat Hematol & Oncol, Chenzhou 423000, Hunan, Peoples R China
[4] First Peoples Hosp Chenzhou, Dept Hepatobiliary Pancreat & Splen Surg, Chenzhou 423000, Hunan, Peoples R China
[5] Univ South China, Sch Pharmaceut Sci, Hengyang Med Sch, Hengyang 421002, Peoples R China
关键词
Near-infrared fluorescence probe; Carboxylesterases; Diabetes mellitus; Hepatocellular carcinoma; Clinical blood serum; BIOMARKER; TISSUE; CELLS;
D O I
10.1016/j.saa.2025.125829
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
Carboxylesterases (CES) is a family of hydrolases, which are mainly localized in the endoplasmic reticulum and cytosol in cells and can catalyze the hydrolysis of carboxylic esters to generate acids and alcohols. The changes of CES level are closely related to the liver disease, such as early onset liver injury induced diabetes and advanced liver cancer. Herein, a new activatable near-infrared (NIR) fluorescent probe PCES (Probe of Carboxylesterases) for imaging CES was rationally designed. The probe can not only specifically sense CES in buffer solution with a 49-fold fluorescence enhancement at 780 nm and a 2.5 mU/mL detection limit, but also can sensitively visualize CES changes with low cytotoxicity and good biocompatibility in living cells. Applying this agent, the fluctuation of CES levels was monitored under high glucose stimulation. The mechanism of ferroptosis in diabetes mellitus has also been preliminarily explored. Besides, PCES was utilized for imaging CES of hepatocellular carcinoma and effectively assisting the tumor surgical operation in vivo. In addition, the practical serum samples were detected from clinical patients suffered diabetes and liver cancer with the help of probe PCES, demonstrating the differentiated CES levels. With the favorable characteristics of fluorescence sensing and practicability of imaging CES in living cells, mice, and clinical serum samples, PCES can help the better understanding for the relation- ships of liver diseases with CES and has the potential as a useful agent for the diagnosis and treatment of clinical liver diseases.
引用
收藏
页数:8
相关论文
共 44 条
  • [1] Laizure S.C., Herring V., Hu Z., Witbrodt K., Parker R.B., The role of human carboxylesterases in drug metabolism: have we overlooked their importance, Pharmacotherapy, 33, pp. 210-222, (2013)
  • [2] Liederer B.M., Borchardt R.T., Enzymes involved in the bioconversion of ester-based prodrugs, J. Pharm. Sci., 95, pp. 1177-1195, (2006)
  • [3] Lavis L.D., Ester bonds in prodrugs, ACS Chem. Biol., 3, pp. 203-206, (2008)
  • [4] Satoh T., Hosokawa M., The mammalian carboxylesterases: from molecules to functions, Annu. Rev. Pharmacol. Toxicol., 38, pp. 257-288, (1998)
  • [5] Hosokawa M., Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs, Molecules, 13, pp. 412-431, (2008)
  • [6] Xiao D., Shi D., Yang D., Barthel B., Koch T.H., Yan B., Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs, Biochem. Pharmacol., 85, pp. 439-447, (2013)
  • [7] Quiroga A.D., Li L., Trotzmuller M., Nelson R., Proctor S.D., Kofeler H., Lehner R., Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia, Hepatology, 56, pp. 2188-2198, (2012)
  • [8] Xu G., Zhang W., Ma M.K., McLeod H.L., Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan, Clin. Cancer Res., 8, pp. 2605-2611, (2002)
  • [9] Na K., Lee E.Y., Lee H.J., Kim K.Y., Lee H., Jeong S.K., Jeong A.S., Cho S.Y., Kim S.A., Song S.Y., Kim K.S., Cho S.W., Kim H., Paik Y.K., Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma, Proteomics, 9, pp. 3989-3999, (2009)
  • [10] Wang D., Zou L., Jin Q., Hou J., Ge G., Yang L., Human carboxylesterases: a comprehensive review, Acta Pharm. Sin. B, 8, pp. 699-712, (2018)